Pfizer And EpiPen Consumers Reach $345M Deal
Pfizer has reached a $345 million settlement with a class of consumers who allege they overpaid for EpiPens because of anti-competitive practices by pharmaceutical companies, potentially clearing the company from having...To view the full article, register now.
Already a subscriber? Click here to view full article